| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T221 |
0-159 |
Sentence |
denotes |
TKIs like sunitinib and erlotinib that specifically inhibit AAK1, a protein regulator that allows passage of the virus into cells, have theorized utility [92]. |
| T222 |
160-307 |
Sentence |
denotes |
Sunitinib is an anti-vascular endothelial growth factor (VEGF) TKI which is used in first-line for treatment of advanced renal cell carcinoma [99]. |
| T223 |
308-471 |
Sentence |
denotes |
Erlotinib is an anti-epidermal growth factor receptor (EGFR) TKI which is used in first-line treatment for metastatic EGFR-mutant non-small cell lung cancer [100]. |
| T224 |
472-649 |
Sentence |
denotes |
Both these TKIs have shown to reduce the infectivity of Dengue and Ebola through in vivo studies with murine models which showed decreased viremia and mortality with treatments. |
| T225 |
650-826 |
Sentence |
denotes |
Moreover, in vitro studies in cultured cells and hepatitis C in this same study showed that use of these TKIs reduced intracellular trafficking and inhibited viral entry [101]. |
| T226 |
827-933 |
Sentence |
denotes |
However, the high doses required to achieve this effect may potentially exhibit harm to patients [92, 93]. |
| T227 |
934-1091 |
Sentence |
denotes |
Regardless, there is potential for cancer patients receiving these therapies to achieve dual benefit as referenced before, but warrant further investigation. |
| T228 |
1092-1221 |
Sentence |
denotes |
Further studies are warranted in tracking the outcomes of cancer patients with COVID-19 and the type of treatments they received. |
